Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the labeling: dosing details (600 mg daily, 21 days on/7 days off in a 28-day cycle, three 200 mg capsules) and the fact that Kisqali is a brand-name cancer drug are supported. Price-related statements are not present in the labeling and are therefore unsupported.
Category Scores
Accurate Statements
Kisqali (ribociclib) adalah obat kanker.
supported
Kisqali tersedia sebagai kapsul 200 mg.
supported
Dosis umum Kisqali adalah 600 mg per hari.
partially supported
600 mg per hari = tiga kapsul 200 mg.
supported
Dosis Kisqali diberikan selama 21 hari on, diikuti 7 hari off.
supported
Siklus pengobatan Kisqali adalah 28 hari.
supported
Kisqali adalah obat bermerek (brand-name).
supported
Unsupported Statements
Harga Kisqali secara umum cukup tinggi karena statusnya sebagai obat bermerek.
Not in FDA labeling; pricing details are not provided in the label.
Harga sangat bergantung pada apakah Anda punya asuransi, copay, potongan harga produsen, atau program bantuan pasien.
Not in FDA labeling; pricing/utilities programs are not described in the label.
Perkiraan biaya bulanan di AS secara daftar (list price) sering berada pada kisaran yang jauh di atas puluhan ribu dolar per bulan.
Not in FDA labeling; no cost data in the label.
Biaya yang Anda keluarkan sendiri bisa jauh lebih rendah jika ada asuransi, diskon, atau program bantuan.
Not in FDA labeling; patient out-of-pocket guidance not provided in the label.
Contradictions
Important Omissions
Contraindications (e.g., hypersensitivity to ribociclib); boxed warnings; embryo-fetal toxicity/pregnancy risk; pediatric safety; drug interactions with CYP3A inhibitors/inducers; need for hepatic impairment dose adjustments; monitoring for hepatotoxicity and QT prolongation.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Omissions include safety-critical elements (contraindications, Boxed warnings, monitoring) but none described claims that would directly pose immediate risk beyond standard safety expectations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Include explicit dosing pattern (21 days on, 7 days off) and safety monitoring details (hepatic function, QT monitoring, DDI considerations) as well as contraindications and boxed warnings.
Suggested Improvement
Add complete safety profile elements from the label (warnings/precautions, contraindications, monitoring recommendations, hepatic impairment dosing adjustments, and CYP3A interaction considerations). Exclude non-label cost-related claims or clearly label them as non-label information.